Otonomy to Present at the J.P. Morgan Healthcare Conference
04. Januar 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear,...
Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update
08. November 2017 16:12 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's Disease
08. November 2017 16:05 ET
|
Otonomy, Inc.
Achieved primary endpoint (p value = 0.029)Company plans to meet with FDA to discuss results and clinical requirements for registrationManagement will review results during third quarter conference...
Otonomy to Report Third Quarter 2017 Financial Results and Provide Corporate Update
01. November 2017 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Provides Business and Financial Update
13. September 2017 07:30 ET
|
Otonomy, Inc.
Actions taken to reduce costs following suspension of OTIVIDEX™ developmentNon-commercial workforce reduced by one-thirdCurrent cash balance expected to fund company into 2020Review underway to...
Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update
03. August 2017 16:12 ET
|
Otonomy, Inc.
SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Report Second Quarter 2017 Financial Results and Provide Corporate Update
27. Juli 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, July 27, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acute Otitis Media with Tympanostomy Tubes
22. Juni 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, June 22, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Host Key Opinion Leader Meeting for Investors on Ménière's Disease
20. Juni 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, June 20, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces OTIPRIO® Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting
12. Mai 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 12, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...